INSERM, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, University of Bordeaux, Bordeaux, France.
University of Costa Rica, San José, Costa Rica.
Helicobacter. 2017 Sep;22 Suppl 1. doi: 10.1111/hel.12412.
Gastric cancer is one of the most incident and deadliest malignancies in the world. Gastric cancer is a heterogeneous disease and the end point of a long and multistep process, which results from the stepwise accumulation of numerous (epi)genetic alterations, leading to dysregulation of oncogenic and tumor suppressor pathways. Gastric cancer stem cells have emerged as fundamental players in cancer development and as contributors to gastric cancer heterogeneity. For this special issue, we will report last year's update on the gastric cancer molecular classification, and in particular address the gastric cancer groups who could benefit from immune checkpoint therapy. We will also review the latest advances on gastric cancer stem cells, their properties as gastric cancer markers and therapeutic targets, and associated signaling pathways. The understanding of the molecular basis underlying gastric cancer heterogeneity and of the role played by gastric cancer stem cells in cancer development and heterogeneity is of major significance, not only for identifying novel targets for cancer prevention and treatment, but also for clinical management and patient stratification for targeted therapies.
胃癌是世界上发病率和致死率最高的恶性肿瘤之一。胃癌是一种异质性疾病,是一个漫长的多步骤过程的终点,它是由许多(表观)遗传改变的逐步积累导致癌基因和肿瘤抑制途径的失调引起的。胃癌干细胞已成为癌症发展的重要参与者,并为胃癌异质性做出贡献。本期特刊将报告胃癌分子分类的最新进展,特别是探讨哪些胃癌群体可能受益于免疫检查点治疗。我们还将回顾胃癌干细胞的最新进展,它们作为胃癌标志物和治疗靶点的特性,以及相关的信号通路。了解胃癌异质性的分子基础以及胃癌干细胞在癌症发展和异质性中的作用具有重要意义,不仅有助于确定癌症预防和治疗的新靶点,还有助于临床管理和靶向治疗的患者分层。